Seeking the capacity to modulate a controlled iPSC induced immune response while minimizing the risk of systemic toxicity, we develop a red/far‐red light‐controlled iPSC vaccine (RIVA) using the intrinsic tumor antigens of iPSCs, where iPSCs were engineered by a red light‐induced protein dimerization (RID) system based on the bacterial chimeric photosensory protein FnBphP and its interaction partner LDB3. This evidence concerns the gene LDB3 and neoplasm.